PMID- 12100367
OWN - NLM
STAT- MEDLINE
DCOM- 20020913
LR  - 20220408
IS  - 0001-6314 (Print)
IS  - 0001-6314 (Linking)
VI  - 106
IP  - 2
DP  - 2002 Aug
TI  - Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic 
      stroke: a randomized, double-blind study.
PG  - 84-92
AB  - OBJECTIVES: To compare the efficacy, safety, and overall risk-benefit profile of 
      enoxaparin and unfractionated heparin (UFH) prophylaxis of venous thromboembolic 
      complications in patients with acute ischaemic stroke. METHODS: Patients with 
      ischaemic stroke resulting in lower-limb paralysis lasting for at least 24 h and 
      necessitating bedrest, were randomized within 48 h of the onset of stroke, and 
      treated with enoxaparin (40 mg subcutaneously once daily) or UFH (5000 IU 
      subcutaneously thrice daily) for 10 +/- 2 days. Main outcome measures were 
      deep-vein thrombosis, pulmonary embolism (PE), death from any cause, intracranial 
      haemorrhage including haemorrhagic infarction, or any other major bleeding. 
      RESULTS: Outcome events occurred within 3 months of stroke in 40/106 patients 
      treated with enoxaparin (37.7%) and 52/106 patients treated with UFH (49.1%, 
      P=0.127). Fewer patients treated with enoxaparin (14, 13.2%) than with UFH (20, 
      18.9%) had evidence of haemorrhagic transformation of ischaemic stroke. 
      CONCLUSIONS: Enoxaparin administered subcutaneously once daily was as safe and 
      effective as subcutaneous UFH given thrice daily in the prevention of 
      thromboembolic events in patients with lower limb paralysis caused by acute 
      ischaemic stroke.
FAU - Hillbom, M
AU  - Hillbom M
AD  - Department of Neutology, Oulu University Hospital Oulu, Finland. 
      matti.hillbom@oulu.fi
FAU - Erila, T
AU  - Erila T
FAU - Sotaniemi, K
AU  - Sotaniemi K
FAU - Tatlisumak, T
AU  - Tatlisumak T
FAU - Sarna, S
AU  - Sarna S
FAU - Kaste, M
AU  - Kaste M
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Acta Neurol Scand
JT  - Acta neurologica Scandinavica
JID - 0370336
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Hemoglobins)
RN  - 9005-49-6 (Heparin)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - EC 2.6.1.2 (Alanine Transaminase)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alanine Transaminase/blood
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - Aspartate Aminotransferases/blood
MH  - Brain Ischemia/complications/drug therapy/mortality
MH  - Double-Blind Method
MH  - Enoxaparin/*administration & dosage/adverse effects
MH  - Female
MH  - Hemoglobins
MH  - Hemorrhage/chemically induced
MH  - Heparin/*administration & dosage/adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Stroke/complications/*drug therapy/mortality
MH  - Tomography, X-Ray Computed
MH  - Treatment Outcome
MH  - Venous Thrombosis/drug therapy/mortality/*prevention & control
EDAT- 2002/07/09 10:00
MHDA- 2002/09/14 10:01
CRDT- 2002/07/09 10:00
PHST- 2002/07/09 10:00 [pubmed]
PHST- 2002/09/14 10:01 [medline]
PHST- 2002/07/09 10:00 [entrez]
AID - 1o215 [pii]
AID - 10.1034/j.1600-0404.2002.01215.x [doi]
PST - ppublish
SO  - Acta Neurol Scand. 2002 Aug;106(2):84-92. doi: 10.1034/j.1600-0404.2002.01215.x.